A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer.

Trial Profile

A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 May 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Testicular cancer
  • Focus Therapeutic Use
  • Acronyms RADIT
  • Most Recent Events

    • 24 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Jun 2014 Interim analysis results in 13 patients presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004049).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top